Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prexasertib companion diagnostic - Acrivon Therapeutics

X
Drug Profile

Prexasertib companion diagnostic - Acrivon Therapeutics

Alternative Names: ACR-368 OncoSignature® companion diagnostic - Acrivon Therapeutics; OncoSignature® companion diagnostic for ACR-368 - Acrivon Therapeutics; Prexasertib OncoSignature®companion diagnostic - Acrivon Therapeutics

Latest Information Update: 06 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acrivon Therapeutics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 28 Jun 2022 Akoya Biosciences and Acrivon Therapeutics enters into collaboration agreement for Prexasertib
  • 22 Jun 2022 Acrivon Therapeutics plans a phase II master protocol trial for Ovarian cancer, Endometrial cancer and Urothelial cancer (Diagnosis) in USA (IV)
  • 22 Jun 2022 Acrivon Therapeutics files an IND application for phase II trial with USFDA in USA for Ovarian cancer, Endometrial cancer and Urothelial cancer before June 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top